Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
Type:
Grant
Filed:
March 24, 2021
Date of Patent:
February 27, 2024
Assignee:
Respira Therapeutics, Inc.
Inventors:
Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
Abstract: A composition comprising particles formed of poly(diaminosulfide) and one or more leptospiral antigens, and methods of making and using the composition, are provided.
Type:
Grant
Filed:
December 11, 2020
Date of Patent:
February 20, 2024
Assignees:
University of Iowa Research Foundation, The United States of America, As Represented by The Secretary of Agriculture
Inventors:
Aliasger K. Salem, Emad I. Wafa, Sean M. Geary, Ned B. Bowden, Jennifer H. Wilson-Welder, David P. Alt
Abstract: Compositions and methods for treating and preventing mosquito infestations are disclosed herein. Also disclosed herein are compositions and methods to reduce or prevent the spread of diseases for which mosquitoes may act as a vector.
Abstract: The present invention provides a functional food that utilizes health-promoting effects of charcoal, is readily ingested, has no adverse side effect, and has an effect of improving and repressing obesity. The functional food includes a charcoal composition having at least one of a bamboo charcoal, a Bincho charcoal, an activated bamboo charcoal and an activated Bincho charcoal, and both of the activated bamboo charcoal and the activated Bincho charcoal have a bulk density of 0.3 to 0.6 g/ml, an average particle size of 10 ?m or smaller, a BET specific surface area of 1000 to 1200 m2/g, and an iodine adsorption amount of 1000 to 1300 mg/g.
Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.
Abstract: A tissue adhesive material that provides fast and robust adhesion even on tissue surfaces covered in bodily fluids. The tissue adhesive material is formed of a hydrophobic matrix and a plurality of bioadhesive microparticles dispersed within the hydrophobic matrix configured such that disposing the adhesive material directly on a fluid covered surface and applying pressure causes the (a) hydrophobic matrix to repel the fluid, (b) the bioadhesive particles to compress forming an adhesive layer, and (c) the bioadhesive particles to form temporary crosslinks followed by covalent crosslinks with the surface.
Type:
Grant
Filed:
December 3, 2020
Date of Patent:
January 30, 2024
Assignees:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors:
Xuanhe Zhao, Hyunwoo Yuk, Xinyu Mao, Christoph Nabzdyk
Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
Type:
Grant
Filed:
January 18, 2022
Date of Patent:
January 30, 2024
Assignee:
The University of Chicago
Inventors:
Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
Abstract: Bio-ink compositions comprising bio-compatible microgels or nanogels are described. The bio-inks can comprise, for example, micro- or nanogels comprising crosslinked poly(N-isopropylacrylamide) (poly-NIPam). The bio-inks can further comprise viscosity control agents, such as poly(ethylene glycol) (PEG), and/or surface tension agents. Three-dimensional (3D) printing (e.g., piezoelectric printing) of the bio-inks can provide 3D printed materials comprising microgel or nanogel assemblies of the bio-ink compositions. These materials can be used as scaffolds for preparing biological tissues for use, for instance, in regenerative medicine.
Type:
Grant
Filed:
April 5, 2019
Date of Patent:
January 23, 2024
Assignee:
North Carolina State University
Inventors:
Ashley Brown, Michael Daniele, Jeremy Nortey, Daniel Chester, Terrika Ngobili
Abstract: Method of building resistance to Covid-19 disease development. The strong link between the distribution of Covid-19 disease (CV) severity across the United States population and that of systemic inflammation, as indicated in the individual's C-reactive protein (CRP) level, explains the widely varied symptomatic responses of individuals afflicted with the virus. The data are consistent with the fewer infections and deaths reported for the Asian countries. The disease pathologies of CV and non-specific interstitial pneumonia (NSIP) patients bear close similarities. Modeling the disease as a chemically reactive process indicates that the virus catalyzes the inflammation driven reaction, causing lung infiltration and injury, up to and including patient death. Prevention methods involving exercise and diet successfully applied for lung stabilization in NSIP also apply to CV mitigation, the goal of which is to achieve pre-disease CRP levels of <10 mg/L, and preferably <3 mg/L, and more preferably <1 mg/L.
Abstract: An antimicrobial composition that includes: an antimicrobial component having at least one quaternary ammonium compound; a synthetic polymer that includes: at least one cationic monomer Ab, optionally, at least one anionic monomer Ba, and optionally, at least one non-ionic monomer Ca; an organic acid; and a surfactant selected from cationic surfactants, amphoteric surfactants and combinations thereof, wherein the composition is free of non-ionic surfactants. This composition when applied to a surface provides robust long lasting disinfection.
Type:
Grant
Filed:
April 2, 2021
Date of Patent:
January 23, 2024
Inventors:
Amit Sehgal, Kamel Ramdani, Christopher Plummer, Huw Evans
Abstract: The invention provides a novel, versatile degradable hydrogel composition, and methods thereof, with precisely tunable stiffness, plasticity (e.g., degree of covalent vs. physical crosslinks) and predictive disintegration rates degradation, allowing controlled disintegration and release of therapeutic cells or pharmaceuticals and/or in vitro 3D cell expansion.
Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
Abstract: The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-? protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor ? (“PPAR?”) to a human or veterinary subject in need of such treatment.
Abstract: The present disclosure provides transparent, elastic silk hydrogels for applications, including corneal reshaping to restore visual acuity and photolithography. The present disclosure also provides methods of photocrosslinking silk fibroin protein using riboflavin as a photoinitiator and exposing such riboflavin doped silk fibroin to light resulting in the formation of a transparent, elastic hydrogel.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
December 5, 2023
Assignee:
Trustees of Tufts College
Inventors:
Fiorenzo G. Omenetto, Matthew B. Applegate, David L. Kaplan
Abstract: A method of treating and preventing Alzheimer's disease (AD) in a subject can include administering to a subject in need thereof a therapeutically effective amount of a nanocomposite formulation including nanosilymarin (silymarin nanoparticles) encapsulated within a collagen-based-polymeric nanoparticulate drug delivery system. The nanocomposite formulation can effectively treat and prevent Alzheimer's disease (AD) at dose ranging from about 100 mg/kg/day to about 300 mg/kg/day.
Type:
Grant
Filed:
June 26, 2023
Date of Patent:
December 5, 2023
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Ahmed Mohammed Abu-Dief Mohammed, Hazem Mohamed Shaheen, Gaber Elsaber Abd El-Wanis Batiha, Manal Aly Shalaby, Amany Mabrouk Abd Elhady Alamh
Abstract: In some aspects, provided herein are antimicrobial compositions comprising partially esterified polygalacturonic acid and certain fatty acids (e.g., caprylic acid). In some embodiments, the antimicrobial composition may be administered (e.g., topically or orally) to a subject, such as a human patient to treat an infection (e.g., an infection comprising a biofilm). In some aspects, improved catheters are provided.
Type:
Grant
Filed:
June 28, 2021
Date of Patent:
November 28, 2023
Assignee:
Board of Regents, The University of Texas System
Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.